DK0559751T3 - Behandling af osteoporosis under anvendelse af væksthormonfrigivende faktor (GRF) i kombination med parathyreoideahormon (PTH) - Google Patents

Behandling af osteoporosis under anvendelse af væksthormonfrigivende faktor (GRF) i kombination med parathyreoideahormon (PTH)

Info

Publication number
DK0559751T3
DK0559751T3 DK92900612.0T DK92900612T DK0559751T3 DK 0559751 T3 DK0559751 T3 DK 0559751T3 DK 92900612 T DK92900612 T DK 92900612T DK 0559751 T3 DK0559751 T3 DK 0559751T3
Authority
DK
Denmark
Prior art keywords
osteoporosis
grf
pth
releasing factor
treatment
Prior art date
Application number
DK92900612.0T
Other languages
English (en)
Inventor
Robert R Recker
Original Assignee
Robert R Recker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Robert R Recker filed Critical Robert R Recker
Application granted granted Critical
Publication of DK0559751T3 publication Critical patent/DK0559751T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK92900612.0T 1990-11-26 1991-11-01 Behandling af osteoporosis under anvendelse af væksthormonfrigivende faktor (GRF) i kombination med parathyreoideahormon (PTH) DK0559751T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61754390A 1990-11-26 1990-11-26

Publications (1)

Publication Number Publication Date
DK0559751T3 true DK0559751T3 (da) 1997-10-06

Family

ID=24474060

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92900612.0T DK0559751T3 (da) 1990-11-26 1991-11-01 Behandling af osteoporosis under anvendelse af væksthormonfrigivende faktor (GRF) i kombination med parathyreoideahormon (PTH)

Country Status (13)

Country Link
US (1) US5164368A (da)
EP (1) EP0559751B1 (da)
JP (1) JP2557779B2 (da)
AT (1) ATE150648T1 (da)
AU (1) AU645874B2 (da)
CA (1) CA2096350C (da)
DE (1) DE69125394T2 (da)
DK (1) DK0559751T3 (da)
ES (1) ES2099245T3 (da)
FI (1) FI106776B (da)
IE (1) IE913858A1 (da)
NZ (1) NZ240482A (da)
WO (1) WO1992009304A1 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5494919A (en) * 1993-11-09 1996-02-27 Merck & Co., Inc. 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5492920A (en) * 1993-12-10 1996-02-20 Merck & Co., Inc. Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
SK56296A3 (en) * 1993-11-09 1997-02-05 Merck & Co Inc Piperidinal, pyrrolidinal and hexahydro-1h-azepinal derivatives, manufacturing process thereof and pharmaceutical compositions containing them
US5721251A (en) * 1993-12-10 1998-02-24 Merck & Co., Inc. Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
US5721250A (en) * 1993-12-23 1998-02-24 Merck & Co. Inc. Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5962427A (en) * 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
US5763416A (en) * 1994-02-18 1998-06-09 The Regent Of The University Of Michigan Gene transfer into bone cells and tissues
US6074840A (en) 1994-02-18 2000-06-13 The Regents Of The University Of Michigan Recombinant production of latent TGF-beta binding protein-3 (LTBP-3)
US5942496A (en) * 1994-02-18 1999-08-24 The Regent Of The University Of Michigan Methods and compositions for multiple gene transfer into bone cells
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
US5731317A (en) * 1995-03-10 1998-03-24 Merck & Co., Inc. Bridged piperidines promote release of growth hormone
US5700775A (en) * 1995-03-24 1997-12-23 Gutniak; Mark K. Method and treatment composition for decreasing patient time in catabolic state after traumatic injury
US5559128A (en) * 1995-04-18 1996-09-24 Merck & Co., Inc. 3-substituted piperidines promote release of growth hormone
US5869041A (en) * 1996-01-12 1999-02-09 The Miriam Hospital Delivery of bioactive compounds to an organism
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
JP2000512274A (ja) * 1996-05-31 2000-09-19 ノボ ノルディスク アクティ―ゼルスカブ 骨粗しょう症の周期的（整合性）治療における成長ホルモン成分及び骨抗吸収剤
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
AU2002300896B2 (en) * 1997-06-19 2006-03-30 Nps Pharmaceuticals, Inc. Method of enhancing bone mineral density
WO1999006563A1 (en) 1997-07-30 1999-02-11 Emory University Novel bone mineralization proteins, dna, vectors, expression systems
US7923250B2 (en) 1997-07-30 2011-04-12 Warsaw Orthopedic, Inc. Methods of expressing LIM mineralization protein in non-osseous cells
EP1119251A4 (en) * 1998-10-07 2004-03-24 Univ Arkansas METHOD FOR SCREENING ON ANALOG BONE THERAPY ACTIVE SUBSTANCES THAT CONTROL APOPTOSIS AND THEIR USE
US6416737B1 (en) 1998-11-19 2002-07-09 Board Of Trustees Of The University Of Arkansas Increasing bone strength with selected bisphosphonates
RU2006143544A (ru) * 2004-05-10 2008-06-20 Нэстек Фармасьютикал Кампани Инк. (Us) Композиции и способ для облегченной чресслизистой доставки паратиреоидного гормона
US20060052306A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. GRAS composition for enhanced mucosal delivery of parathyroid hormone
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
US7994129B2 (en) * 2005-11-10 2011-08-09 Michigan Technological University Methods of using black bear parathyroid hormone
US20080051332A1 (en) * 2005-11-18 2008-02-28 Nastech Pharmaceutical Company Inc. Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
AR079234A1 (es) 2009-12-01 2012-01-04 Abbott Lab Derivados heterociclicos condensados nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos para tratar afecciones oncologicas, del sistema nervioso y/o del sistema inmune.
WO2011071480A1 (en) 2009-12-07 2011-06-16 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870094A (en) * 1984-05-02 1989-09-26 Uniroyal Chemical Company, Inc. Substituted imidazoles and triazoles
US4870054A (en) * 1985-09-27 1989-09-26 Recker Robert R Treatment for osteoporosis using GRF or a biologically active analog thereof
US4710382A (en) * 1985-09-27 1987-12-01 Recker Robert R Treatment for osteoporosis using hGRF(1-40)NH2
US4833125A (en) * 1986-12-05 1989-05-23 The General Hospital Corporation Method of increasing bone mass
US4833123A (en) * 1987-10-08 1989-05-23 Sumitomo Chemical Company Limited Yellow dye-donor element used in thermal transfer and thermal transfer and thermal transfer sheet using it
WO1989007113A1 (en) * 1988-01-29 1989-08-10 The Upjohn Company Grf analogs

Also Published As

Publication number Publication date
FI106776B (fi) 2001-04-12
DE69125394D1 (de) 1997-04-30
EP0559751B1 (en) 1997-03-26
CA2096350C (en) 2001-10-16
EP0559751A4 (en) 1994-07-13
ATE150648T1 (de) 1997-04-15
JP2557779B2 (ja) 1996-11-27
AU645874B2 (en) 1994-01-27
US5164368A (en) 1992-11-17
JPH06502863A (ja) 1994-03-31
CA2096350A1 (en) 1992-05-27
AU9073591A (en) 1992-06-25
IE913858A1 (en) 1992-06-03
FI932385A0 (fi) 1993-05-26
NZ240482A (en) 1997-06-24
EP0559751A1 (en) 1993-09-15
DE69125394T2 (de) 1997-08-21
FI932385A (fi) 1993-05-26
ES2099245T3 (es) 1997-05-16
WO1992009304A1 (en) 1992-06-11

Similar Documents

Publication Publication Date Title
DK0559751T3 (da) Behandling af osteoporosis under anvendelse af væksthormonfrigivende faktor (GRF) i kombination med parathyreoideahormon (PTH)
RU2224539C2 (ru) Заживление переломов с помощью аналогов пептида, подобного паратироидному гормону (ртнrр)
CA2032123A1 (fr) Dispositif de renfort et de soutien de la coiffe des rotateurs d'une articulation d'epaule d'individus
YU46794A (sh) Farmaceutska formulacija na bazi paratiroidnog hormona i raloksifena
RU93054017A (ru) Способ лечения остеопороза, композиция для лечения остеопороза, применение активно действующего на кости фосфоната и эстрогенного гормона для лечения остеопороза
CA2124792A1 (en) Methods for the Treatment of Osteoporosis Using Bisphosphonates and Parathyroid Hormone
BG100517A (en) Combination of bisphosphonates and growth hormone secretagogues
ES2055845T3 (es) Composicion farmaceutica para el tratamiento de la osteoporosis.
DE58903316D1 (de) Spreizduebel fuer eine zementfreie verankerung von knochenimplantaten.
DK0725648T3 (da) Leverspecifikke farmaceutiske aktivstoffer
ATE208612T1 (de) Biologisch erodierbare vorrichtung zur verabreichung von wirkstoffen
SE8405596D0 (sv) A method of producing a mono- or multilayered prothesis material and the material hereby obtained
AT388096B (de) Implantat zur befestigung von zahnprothesen
NO305581B1 (no) Anvendelse av et benaktivt fosfonat i kombinasjon med et °strogenhormon, og preparat i enhetsdoseform for behandling av osteoporose
DK1001802T3 (da) Farmaceutisk kombinationspræparat af parathyroidhormon og en knogleresorptionsinhibitor
GEP20033095B (en) Parathyroid Hormone Analogues for the Treatment of Osteoporosis
ATE80028T1 (de) Schulterspan.
DE69316013T2 (de) Verwendung von phosphinate zur behandlung der osteoporose
ATE110967T1 (de) Knochenersatzmaterial und knochenzement.
EP0493737A3 (en) Agent for the treatment of bone diseases containing basic fibroblast growth factor
FR2707479B1 (fr) Dispositif de fixation par ciment d'un implant prothétique dans une cavité osseuse.
ATA223591A (de) Verfahren zur herstellung einer zur kontinuierlichen und kontrollierten abgabe eines natürlichen oder synthetischen peptids bestimmten pharmazeutischen zusammensetzung, insbesondere in form von mikrokapseln bzw. implantaten
DE69915852D1 (de) Lhrh-analoga zur behandlung der osteoporose
OA09766A (en) "Treatment of anxiety in benzodiazepine-withdrawn patients".
RU96100080A (ru) Лечение состояний, связанных с нарушением уровня паратгормона